Bimini Biotech

BIMINI Biotech is a private, preclinical-stage biotech company pioneering a novel approach to treating cancer and autoimmune disorders through modulation of the Wiskott-Aldrich Syndrome protein (WASp). The company has built a proprietary portfolio of small-molecule WASp modulators, including its lead candidate BM-011, licensed from the Institute of Oncology Research. With a seasoned leadership team and backing from public grants and investors like InnovationQuarter, BIMINI is advancing its lead programs toward first-in-human studies, targeting significant unmet needs in hematological cancers and autoimmunity.

Proprietary platform for developing small-molecule modulators (agonists and antagonists) of the Wiskott-Aldrich Syndrome protein (WASp), a key regulator of actin cytoskeleton dynamics in immune cells.

Direct competition targeting WASp is currently minimal, making BIMINI a potential pioneer. However, indirect competition is fierce across its target indications from large pharma and biotech companies developing other targeted therapies, immunotherapies, and novel small molecules. Success will depend on demonstrating superior or complementary efficacy to existing standards of care.